search
Back to results

The Effects of Muscle Training in Coronary Artery Patients With Metabolic Syndrome

Primary Purpose

Metabolic Syndrome, Coronary Artery Disease

Status
Completed
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
Neuromuscular Electrical Stimulation
Inspirator Muscle Training
Peripheral Muscle Training
Sponsored by
Istanbul Medipol University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metabolic Syndrome focused on measuring Metabolic Syndrome, Coronary Artery Patients, Neuromuscular Electrical Stimulation, Respiratory Muscle Training, Peripheral Muscle Training

Eligibility Criteria

35 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Stable coronary artery disease with metabolic syndrome diagnosis
  2. The ejection fraction(EF) = % 40 and EF >% 40,
  3. Participation to the study will be in a voluntary basis

Exclusion Criteria:

  1. Over 80 years,
  2. EF <40% or New York Heart Association (NYHA) class III-IV
  3. Chronic obstructive pulmonary disease (COPD) and respiratory tract infection,
  4. Documented diagnosis of pulmonary, neurological,orthopedic, renal, hepatic, gastrointestinal, endocrine, oncologic
  5. New or suspected thromboembolic events
  6. Severe refractory hypertension
  7. Acute myocardial infarction and pulmonary edema in the last 6 months,
  8. Coronary artery revascularization attempts (percutaneous transluminal coronary angioplasty and coronary artery bypass surgery) and previous valve surgery in the last 6 months,
  9. Cardiac pacemaker

Sites / Locations

  • Kıymet Muammer

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

NMES and Peripheral Muscle Training

IMT and Peripheral Muscle Training

Peripheral Muscle Training

Arm Description

Neuromuscular Electrical Stimulation (NMES) and Peripheral Muscle Training NMES frequency will be 30 Hertz and the application time will be 30 minutes.Treatment will be programmed for 3 days per week. Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.

Inspirator Muscle Training (IMT) and Peripheral Muscle Training IMT will be applied 7 days per week, twice a day for 15 minutes. Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week. The program will continue for 6 weeks.

Peripheral Muscle Training Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.

Outcomes

Primary Outcome Measures

Maximum Inspiratory Pressure (MIP)
Change from baseline Maximum Inspiratory Pressure (MIP) at 6 weeks. Respiratory muscle strength will be measured according to the portable, electronic intraoral pressure measuring device (MicroRPM, Micro Medical UK), American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria. The most commonly used method for evaluating respiratory muscles is MIP measurement is a non-invasive technique.
Maximum Expiratory Pressure (MEP)
Change from baseline Maximum Expiratory Pressure (MEP) at 6 weeks. Respiratory muscle strength will be measured according to the portable, electronic intraoral pressure measuring device (MicroRPM, Micro Medical UK), American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria. The most commonly used method for evaluating respiratory muscles is MEP measurement is a non-invasive technique.
Functional capacity
Change from baseline functional capacity test at 6 weeks. Functional capacity will be assessed by the 6 minute walking test. The test will be performed according to American Thoracic Society (ATS) criteria. Patients will be allowed to rest for 10 minutes before the test. Heart rate, blood pressure, respiratory frequency, oxygen saturation, fatigue and dyspnea perception will be recorded before and after the test. Walking distance will be calculated.

Secondary Outcome Measures

Forced Vital Capacity (FVC)
Change from baseline Forced Vital Capacity (FVC) in respiratory function test at 6 weeks. FVC will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
Forced Expiratory Volume 1 second (FEV1)
Change from baseline Forced Expiratory Volume 1 second (FEV1) in respiratory function . FEV1 will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
Forced Expiratory Volume 1 second / Forced Vital Capacity (FEV1 / FVC)
Change from baseline FEV1 / FVC in respiratory function test at 6 weeks. FEV1 / FVC will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
Forced Expiratory flow from between 25% to 75% of Vital Capacity (FMF 25-75)
Change from baseline Forced Expiratory flow from between 25% to 75% of Vital Capacity . FMF will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
Peak flow rate (PEF)
Change from baseline Peak flow rate (PEF) in respiratory function test at 6 weeks. PEF will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
Dyspnea
Change from baseline Dyspnea score of Medical Research Council (MRC) at 6 weeks. It will be evaluated by MRC.
Peripheral muscle strength
Change from baseline peripheral muscle strength at 6 weeks. Lower extremity will be evaluated by 'sit to stand' test. Upper extremity will be evaluated by 'handgrip test'.
Maximal exercise capacity
Change from baseline treadmill test at 6 weeks. It will be evaluated by treadmill test.
Physical Activity
Change from baseline physical activity scores at 6 weeks. International Physical Activity Questionnaire (IPAQ) - Short Form (Turkish version of scale ).This questionnaire assesses, in minutes, the physical activity performed by the volunteers during the period of one week. The IPAQ considered all activities carried out by the volunteer (e.g. leisure, sport, exercise, and activities at home or in the garden). According to the responses, the volunteer is considered very active, active, irregularly active or sedentary, according to the intensity and time of the exercises practiced over the last week.
Quality of life level
Change from baseline quality of life scores at 6 weeks. Short Form (SF-36) Health Survey (Turkish version of scale) The SF-36 is a 36 item questionnaire that measures eight multi-item dimensions of health: physical functioning (10 items) social functioning (2 items) role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), mental health (5 items), energy/vitality (4 items), pain (2 items), and general health perception (5 items). For each dimension item scores are coded, summed, and transformed on to a scale from 0 (worst possible health state measured by the questionnaire) to 100 (best possible health state).
Depression level
Change from baseline depression scores at 6 weeks. Beck Depression questionnaire will be administered. The Beck Depression Questionnaire is an assessment scale that determines the risk of depression and the level of depressive symptoms and the measure of change in severity. It consists of 21 items. It provides 4 types of measurements. Each question contains 4 options. Each item gets a progressive score between 0-3 and the total score is obtained by their aggregation. The total varies from 0 to 63 points. Higher scores indicate higher depression.
Evaluation of sleep quality
Change from baseline evaluation of sleep quality scores at 6 weeks.The Pittsburgh Sleep Quality Index (PSQI) assess sleep quality. It consists of seven subscales: subjective sleep efficiency, sleep latency, sleep duration, sleep quality, sleep disturbance, sleep medication use, and daytime dysfunction due to sleepiness. Subscales yield a score from 0 to 3 and PSQI total score of >5 is indicative of poor sleep.
Anthropometric measurements
Change from baseline anthropometric measurements at 6 weeks. Waist, hip and abdominal circumference measurements will be assessed.The skinfold thickness will be measured with the skinfold caliper. These measurements will be made from specific measurement sites of chest, biceps, triceps, subscapular, abdominal, suprailiac, quadriceps, gastrocnemius.
Evaluation of fasting blood glucose in blood biochemistry
Change from baseline fasting blood glucose measurements at 6 weeks. The blood glucose concentration in blood biochemistry will be assessed.
Evaluation of High Density Lipoprotein in blood biochemistry
Change from baseline High Density Lipoprotein measurements at 6 weeks. The High Density Lipoprotein in blood biochemistry will be assessed.
Evaluation of Low Density Lipoprotein in blood biochemistry
Change from baseline Low Density Lipoprotein measurements at 6 weeks. The Low Density Lipoprotein in blood biochemistry will be assessed.
Evaluation of triglyceride in blood biochemistry
Change from baseline triglyceride measurements at 6 weeks. The triglyceride in blood biochemistry will be assessed.
Evaluation of C-Reactive Protein (CRP) in blood biochemistry
Change from baseline C-Reactive Protein (CRP) measurements at 6 weeks. The C-Reactive Protein (CRP) in blood biochemistry will be assessed.
Evaluation of sedimentation in blood biochemistry
Change from baseline sedimentation measurements at 6 weeks. The sedimentation in blood biochemistry will be assessed.
Evaluation of Antistreptolysin O (ASO) in blood biochemistry
Change from baseline Antistreptolysin O (ASO) measurements at 6 weeks. The Antistreptolysin O (ASO) in blood biochemistry will be assessed.
Evaluation of Creatine phosphokinase (CPK) in blood biochemistry
Change from baseline Creatine phosphokinase (CPK) measurements at 6 weeks. The Creatine phosphokinase (CPK) in blood biochemistry will be assessed.
Evaluation of Thyroid-Stimulating Hormone (TSH) in blood biochemistry
Change from baseline Thyroid-Stimulating Hormone (TSH) measurements at 6 weeks. The Thyroid-Stimulating Hormone (TSH) in blood biochemistry will be assessed.
Evaluation of Brain Natriuretic Peptide (Pro-BNP) in blood biochemistry
Change from baseline Brain Natriuretic Peptide (Pro-BNP) measurements at 6 weeks. The Brain Natriuretic Peptide (Pro-BNP) in blood biochemistry will be assessed.
Evaluation of complete blood count in blood biochemistry
Change from baseline complete blood count measurements at 6 weeks. The complete blood count in blood biochemistry will be assessed.
Evaluation of ferritin in blood biochemistry
Change from baseline ferritin measurements at 6 weeks. The ferritin in blood biochemistry will be assessed.
Evaluation of uric acid in blood biochemistry
Change from baseline uric acid measurements at 6 weeks. The uric acid in blood biochemistry will be assessed.
Evaluation of creatinine in blood biochemistry
Change from baseline creatinine measurements at 6 weeks. The creatinine in blood biochemistry will be assessed.

Full Information

First Posted
April 14, 2018
Last Updated
January 26, 2019
Sponsor
Istanbul Medipol University Hospital
Collaborators
Istanbul University
search

1. Study Identification

Unique Protocol Identification Number
NCT03523026
Brief Title
The Effects of Muscle Training in Coronary Artery Patients With Metabolic Syndrome
Official Title
The Effects of Peripheral and Respiratory Muscle Training in Coronary Artery Patients With Metabolic Syndrome: A Randomized, Prospective, Double-Blind and Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
April 15, 2018 (Actual)
Primary Completion Date
November 30, 2018 (Actual)
Study Completion Date
December 30, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Istanbul Medipol University Hospital
Collaborators
Istanbul University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to investigate the effects of peripheral and respiratory muscle training on respiratory muscle strength, respiratory functions, exercise capacity and quality of life in coronary artery patients with metabolic syndrome. Prospectively, randomly, double-blind, and controlled study. Stable coronary artery patients with metabolic syndrome will be included to the study from the Istanbul University Cardiology Institute clinic. Patients will be randomized into 3 groups; Neuromuscular Electrical Stimulation (NMES) and Peripheral Muscle Training Group (n: 20): 3 days per week for 6 weeks duration. Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation three times per week for 6 weeks.Inspirator Muscle Training (IMT) and peripheral muscle training Group (n: 20): IMT will be applied 7 days per week, twice a day for 15 minutes. The program will continue for 6 weeks duration under weekly control of the investigator. Training intensity will set at 30% of the maximum inspiratory pressure.Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation three times per week for 6 weeks. Peripheral Muscle Training Group (n: 20): Exercise will be applied by elastic band and Proprioceptive Neuromuscular Facilitation three times per week for 6 weeks.Parameters will be recorded before and after training. Evaluation parameters:Demographic and anthropometric measurements, respiratory function test,respiratory muscle strength,dyspnea, peripheral muscle strength, 6 minutes walking test, physical activity, quality of life, depression, sleep quality and laboratory evaluation.
Detailed Description
Metabolic syndrome (MS) is a fatal endocrinopathy that appears with insulin resistance and is associated with systemic disorders such as abdominal obesity, glucose intolerance or diabetes mellitus, dyslipidemia, hypertension and coronary artery disease (CAD). The metabolic syndrome, which is regarded as an important public health problem in the world, shows a global increase. Studies have showed that increased risk for cardiopulmonary disease is associated with people with metabolic syndrome. In the treatment of cardiopulmonary risk factors, therapeutic lifestyle changes and exercise are recommended in primary care strategy. Exercise training programs have been found to have positive effects on cardiopulmonary and metabolic parameters.It has been shown that respiratory functions are also adversely affected in these patients. In patients with metabolic syndrome, FEV1 and FVC were found to be influenced by decreased respiratory function and restrictive ventilation impairment. Decreased respiratory functions and physical activity in patients with Metabolic Syndrome accompanied by multifactorial risks and complications will adversely affect quality of life. There are no studies in the literature that investigate the effects of peripheral and respiratory muscle training in patients with Metabolic Syndrome. Therefore, we aimed to investigate the effect of peripheral and respiratory muscle training on respiratory muscle strength, respiratory functions, exercise capacity and quality of life in patients with Metabolic Syndrome. This study also aimed to contribute to the international literature by applying respiratory muscle training in patients with coronary artery disease with metabolic syndrome. In addition, in clinically structured rehabilitation programs, in coronary artery disease patients with metabolic syndrome will be provided with a questioning of the importance of respiratory muscle training. The study will be planned as prospective, randomized, double blind and controlled. Access to the patients will be provided through an archive of patient records and a screening through the online system of the outpatient clinic. Before and after the training patients' effort tests and biochemical tests will be requested. Evaluations before and after the training will be done by another physiotherapist. The study will be conducted prospectively, randomly, double-blind, and controlled. Patients will be randomized into 3 groups. NMES and Peripheral Muscle Training Group (n: 20). IMT and Peripheral Muscle Training Group (n: 20), Peripheral Muscle Training Group (n = 20). NMES and Peripheral Muscle Training Group: NMES to rectus abdominis will be applied using 4 carbon silicon electrode. In the first sessions, patients ECG will be checked. Patients will be in semi-fowler position (30º),with their lower limbs to be in extension and upper limbs at their sides. The NMES frequency will be at 30 Hertz and the application time will be 30 minutes. Treatment will be programmed for 3 days per week. The patients will coordinate their breath (inspiration) with the contraction which will be generated by the electrical current. Peripheral muscle training will also be given. Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation three times per week for 6 weeks. IMT and Peripheral Muscle Training Group: IMT will be applied 7 days per week, twice a day for 15 minutes. The program will continue for 6 weeks duration under weekly control of the investigator. Training intensity will set at 30% of the maximum inspiratory pressure. Peripheral muscle training will also be given. Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation three times per week for 6 weeks. Peripheral Muscle Training Group: Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation three times per week for 6 weeks. The rehabilitation program duration will be 6 weeks in all groups. Changes in parameters will be analyzed before and after treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome, Coronary Artery Disease
Keywords
Metabolic Syndrome, Coronary Artery Patients, Neuromuscular Electrical Stimulation, Respiratory Muscle Training, Peripheral Muscle Training

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
NMES and Peripheral Muscle Training
Arm Type
Experimental
Arm Description
Neuromuscular Electrical Stimulation (NMES) and Peripheral Muscle Training NMES frequency will be 30 Hertz and the application time will be 30 minutes.Treatment will be programmed for 3 days per week. Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
Arm Title
IMT and Peripheral Muscle Training
Arm Type
Experimental
Arm Description
Inspirator Muscle Training (IMT) and Peripheral Muscle Training IMT will be applied 7 days per week, twice a day for 15 minutes. Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week. The program will continue for 6 weeks.
Arm Title
Peripheral Muscle Training
Arm Type
Experimental
Arm Description
Peripheral Muscle Training Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
Intervention Type
Device
Intervention Name(s)
Neuromuscular Electrical Stimulation
Intervention Description
Neuromuscular Electrical Stimulation(NMES) to rectus abdominis will be applied using 4 carbon silicon electrode. In the first sessions, patients ECG will be checked. Patients will be in semi-fowler position (30º),with their lower limbs to be in extension and upper limbs at their sides. The NMES frequency will be at 30 Hertz and the application time will be 30 minutes. Treatment will be programmed for 3 days per week. The patients will coordinate their breath (inspiration) with the contraction which will be generated by the electrical current. The program will continue for 6 weeks.
Intervention Type
Other
Intervention Name(s)
Inspirator Muscle Training
Intervention Description
Inspirator Muscle Training(IMT) will be applied 7 days per week, twice a day for 15 minutes. The program will continue for 6 weeks duration under weekly control of the investigator.Training intensity will set at 30% of the maximum inspiratory pressure.
Intervention Type
Other
Intervention Name(s)
Peripheral Muscle Training
Intervention Description
Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
Primary Outcome Measure Information:
Title
Maximum Inspiratory Pressure (MIP)
Description
Change from baseline Maximum Inspiratory Pressure (MIP) at 6 weeks. Respiratory muscle strength will be measured according to the portable, electronic intraoral pressure measuring device (MicroRPM, Micro Medical UK), American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria. The most commonly used method for evaluating respiratory muscles is MIP measurement is a non-invasive technique.
Time Frame
Baseline and 6 weeks
Title
Maximum Expiratory Pressure (MEP)
Description
Change from baseline Maximum Expiratory Pressure (MEP) at 6 weeks. Respiratory muscle strength will be measured according to the portable, electronic intraoral pressure measuring device (MicroRPM, Micro Medical UK), American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria. The most commonly used method for evaluating respiratory muscles is MEP measurement is a non-invasive technique.
Time Frame
Baseline and 6 weeks
Title
Functional capacity
Description
Change from baseline functional capacity test at 6 weeks. Functional capacity will be assessed by the 6 minute walking test. The test will be performed according to American Thoracic Society (ATS) criteria. Patients will be allowed to rest for 10 minutes before the test. Heart rate, blood pressure, respiratory frequency, oxygen saturation, fatigue and dyspnea perception will be recorded before and after the test. Walking distance will be calculated.
Time Frame
Baseline and 6 weeks
Secondary Outcome Measure Information:
Title
Forced Vital Capacity (FVC)
Description
Change from baseline Forced Vital Capacity (FVC) in respiratory function test at 6 weeks. FVC will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
Time Frame
Baseline and 6 weeks
Title
Forced Expiratory Volume 1 second (FEV1)
Description
Change from baseline Forced Expiratory Volume 1 second (FEV1) in respiratory function . FEV1 will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
Time Frame
Baseline and 6 weeks
Title
Forced Expiratory Volume 1 second / Forced Vital Capacity (FEV1 / FVC)
Description
Change from baseline FEV1 / FVC in respiratory function test at 6 weeks. FEV1 / FVC will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
Time Frame
Baseline and 6 weeks
Title
Forced Expiratory flow from between 25% to 75% of Vital Capacity (FMF 25-75)
Description
Change from baseline Forced Expiratory flow from between 25% to 75% of Vital Capacity . FMF will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
Time Frame
Baseline and 6 weeks
Title
Peak flow rate (PEF)
Description
Change from baseline Peak flow rate (PEF) in respiratory function test at 6 weeks. PEF will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
Time Frame
Baseline and 6 weeks
Title
Dyspnea
Description
Change from baseline Dyspnea score of Medical Research Council (MRC) at 6 weeks. It will be evaluated by MRC.
Time Frame
Baseline and 6 weeks
Title
Peripheral muscle strength
Description
Change from baseline peripheral muscle strength at 6 weeks. Lower extremity will be evaluated by 'sit to stand' test. Upper extremity will be evaluated by 'handgrip test'.
Time Frame
Baseline and 6 weeks
Title
Maximal exercise capacity
Description
Change from baseline treadmill test at 6 weeks. It will be evaluated by treadmill test.
Time Frame
Baseline and 6 weeks
Title
Physical Activity
Description
Change from baseline physical activity scores at 6 weeks. International Physical Activity Questionnaire (IPAQ) - Short Form (Turkish version of scale ).This questionnaire assesses, in minutes, the physical activity performed by the volunteers during the period of one week. The IPAQ considered all activities carried out by the volunteer (e.g. leisure, sport, exercise, and activities at home or in the garden). According to the responses, the volunteer is considered very active, active, irregularly active or sedentary, according to the intensity and time of the exercises practiced over the last week.
Time Frame
Baseline and 6 weeks
Title
Quality of life level
Description
Change from baseline quality of life scores at 6 weeks. Short Form (SF-36) Health Survey (Turkish version of scale) The SF-36 is a 36 item questionnaire that measures eight multi-item dimensions of health: physical functioning (10 items) social functioning (2 items) role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), mental health (5 items), energy/vitality (4 items), pain (2 items), and general health perception (5 items). For each dimension item scores are coded, summed, and transformed on to a scale from 0 (worst possible health state measured by the questionnaire) to 100 (best possible health state).
Time Frame
Baseline and 6 weeks
Title
Depression level
Description
Change from baseline depression scores at 6 weeks. Beck Depression questionnaire will be administered. The Beck Depression Questionnaire is an assessment scale that determines the risk of depression and the level of depressive symptoms and the measure of change in severity. It consists of 21 items. It provides 4 types of measurements. Each question contains 4 options. Each item gets a progressive score between 0-3 and the total score is obtained by their aggregation. The total varies from 0 to 63 points. Higher scores indicate higher depression.
Time Frame
Baseline and 6 weeks
Title
Evaluation of sleep quality
Description
Change from baseline evaluation of sleep quality scores at 6 weeks.The Pittsburgh Sleep Quality Index (PSQI) assess sleep quality. It consists of seven subscales: subjective sleep efficiency, sleep latency, sleep duration, sleep quality, sleep disturbance, sleep medication use, and daytime dysfunction due to sleepiness. Subscales yield a score from 0 to 3 and PSQI total score of >5 is indicative of poor sleep.
Time Frame
Baseline and 6 weeks
Title
Anthropometric measurements
Description
Change from baseline anthropometric measurements at 6 weeks. Waist, hip and abdominal circumference measurements will be assessed.The skinfold thickness will be measured with the skinfold caliper. These measurements will be made from specific measurement sites of chest, biceps, triceps, subscapular, abdominal, suprailiac, quadriceps, gastrocnemius.
Time Frame
Baseline and 6 weeks
Title
Evaluation of fasting blood glucose in blood biochemistry
Description
Change from baseline fasting blood glucose measurements at 6 weeks. The blood glucose concentration in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks
Title
Evaluation of High Density Lipoprotein in blood biochemistry
Description
Change from baseline High Density Lipoprotein measurements at 6 weeks. The High Density Lipoprotein in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks
Title
Evaluation of Low Density Lipoprotein in blood biochemistry
Description
Change from baseline Low Density Lipoprotein measurements at 6 weeks. The Low Density Lipoprotein in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks
Title
Evaluation of triglyceride in blood biochemistry
Description
Change from baseline triglyceride measurements at 6 weeks. The triglyceride in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks
Title
Evaluation of C-Reactive Protein (CRP) in blood biochemistry
Description
Change from baseline C-Reactive Protein (CRP) measurements at 6 weeks. The C-Reactive Protein (CRP) in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks
Title
Evaluation of sedimentation in blood biochemistry
Description
Change from baseline sedimentation measurements at 6 weeks. The sedimentation in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks
Title
Evaluation of Antistreptolysin O (ASO) in blood biochemistry
Description
Change from baseline Antistreptolysin O (ASO) measurements at 6 weeks. The Antistreptolysin O (ASO) in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks
Title
Evaluation of Creatine phosphokinase (CPK) in blood biochemistry
Description
Change from baseline Creatine phosphokinase (CPK) measurements at 6 weeks. The Creatine phosphokinase (CPK) in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks
Title
Evaluation of Thyroid-Stimulating Hormone (TSH) in blood biochemistry
Description
Change from baseline Thyroid-Stimulating Hormone (TSH) measurements at 6 weeks. The Thyroid-Stimulating Hormone (TSH) in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks
Title
Evaluation of Brain Natriuretic Peptide (Pro-BNP) in blood biochemistry
Description
Change from baseline Brain Natriuretic Peptide (Pro-BNP) measurements at 6 weeks. The Brain Natriuretic Peptide (Pro-BNP) in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks
Title
Evaluation of complete blood count in blood biochemistry
Description
Change from baseline complete blood count measurements at 6 weeks. The complete blood count in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks
Title
Evaluation of ferritin in blood biochemistry
Description
Change from baseline ferritin measurements at 6 weeks. The ferritin in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks
Title
Evaluation of uric acid in blood biochemistry
Description
Change from baseline uric acid measurements at 6 weeks. The uric acid in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks
Title
Evaluation of creatinine in blood biochemistry
Description
Change from baseline creatinine measurements at 6 weeks. The creatinine in blood biochemistry will be assessed.
Time Frame
Baseline and 6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Stable coronary artery disease with metabolic syndrome diagnosis The ejection fraction(EF) = % 40 and EF >% 40, Participation to the study will be in a voluntary basis Exclusion Criteria: Over 80 years, EF <40% or New York Heart Association (NYHA) class III-IV Chronic obstructive pulmonary disease (COPD) and respiratory tract infection, Documented diagnosis of pulmonary, neurological,orthopedic, renal, hepatic, gastrointestinal, endocrine, oncologic New or suspected thromboembolic events Severe refractory hypertension Acute myocardial infarction and pulmonary edema in the last 6 months, Coronary artery revascularization attempts (percutaneous transluminal coronary angioplasty and coronary artery bypass surgery) and previous valve surgery in the last 6 months, Cardiac pacemaker
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kıymet Muammer, MSc PT
Organizational Affiliation
Istanbul University Cardiology Institute, Department of Physiotherapy and Rehabilitation
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Fatma Karantay Mutluay, Professor
Organizational Affiliation
Medipol University, Health Sciences Faculty, Physiotherapy and Rehabilitation
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Rengin Demir, Professor
Organizational Affiliation
Istanbul University Cardiology Institute, Department of Physiotherapy and Rehabilitation,
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Alev Arat Özkan, Professor
Organizational Affiliation
Istanbul University Cardiology Institute,Catheter Laboratory
Official's Role
Study Chair
Facility Information:
Facility Name
Kıymet Muammer
City
Istanbul
State/Province
Fatih/Istanbul
ZIP/Postal Code
34096
Country
Turkey

12. IPD Sharing Statement

Citations:
PubMed Identifier
32877886
Citation
Muammer K, Mutluay F, Demir R, Ozkan AA. Effects of peripheral and different inspiratory muscle training methods in coronary artery disease patients with metabolic syndrome: A randomized-controlled trial. Respir Med. 2020 Oct;172:106119. doi: 10.1016/j.rmed.2020.106119. Epub 2020 Aug 22.
Results Reference
derived

Learn more about this trial

The Effects of Muscle Training in Coronary Artery Patients With Metabolic Syndrome

We'll reach out to this number within 24 hrs